Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | CASP7 | P55210 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394300 | 0.76 | TAAR1 (0.76) | TAAR1TDP1POLBKDM4EALDH1A1 | |
| SCHEMBL19662062 | 0.74 | TAAR1 (0.58) | TAAR1TDP1POLBKDM4EALDH1A1 | |
| SCHEMBL30487922 | 0.74 | TAAR1 (0.73) | TAAR1TDP1POLBKDM4EALDH1A1 | |
| SCHEMBL244155 | 0.74 | — | — | |
| SCHEMBL1799678 | 0.73 | ALDH1A1 (0.63) | TAAR1TDP1POLBKDM4EALDH1A1 | |
| SCHEMBL7191487 | 0.73 | LPL (0.46) | ALDH1A1LMNALPLLIPGMAPK1 | |
| SCHEMBL28323221 | 0.72 | TAAR1 (0.62) | TAAR1TDP1POLBKDM4EALDH1A1 | |
| SCHEMBL162083 | 0.72 | TAAR1 (0.62) | TAAR1TDP1POLBKDM4EALDH1A1 | |
| SCHEMBL11073018 | 0.70 | TAAR1 (0.60) | TAAR1TDP1POLBKDM4EALDH1A1 | |
| SCHEMBL7266912 | 0.70 | ALDH1A1 (0.48) | TAAR1TDP1POLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115073401-B | 2,3 '-bisfuran compound, 2,3' -oligomeric furan compound, and preparation methods and applications thereof | 华南理工大学 | 2023-07-14 | — | — | CN | claimed |
| CN-115073401-A | 2,3 '-difuran compound and 2,3' -oligofuran compound, and preparation method and application thereof | 华南理工大学 | 2022-09-20 | — | — | CN | claimed |
| EP-4126833-B1 | N-PHENYL-3-MERCAPTOPROPANAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2026-05-20 | — | — | EP | disclosed |
| EP-3870572-B1 | COMPOUNDS TARGETING MUTANT CALRETICULIN | MYELOPRO DIAGNOSTICS AND RES GMBH (AT) | 2026-05-06 | — | — | EP | disclosed |
| US-12616670-B2 | N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infections | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2026-05-05 | — | — | US | disclosed |
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| EP-4698170-A1 | GLYCINAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SALMONELLOSIS | Eberhard-Karls-Universität Tübingen (DE) | 2026-02-25 | — | — | EP | disclosed |
| US-12528783-B2 | PqsR inverse agonists | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2026-01-20 | — | — | US | disclosed |
| EP-4204397-B1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LASB | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2025-12-03 | — | — | EP | disclosed |
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2025-11-27 | — | — | US | disclosed |
| WO-2025242745-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA ELASTASE (LASB) FOR THE TREATMENT OF PSEUDOMONAS KERATITIS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-11-27 | — | — | WO | disclosed |
| EP-1622870-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | Prosidion Ltd. (GB) | 2006-02-08 | — | — | EP | disclosed |
| US-20050249740-A1 | Tubulysin conjugates | R & D BIOPHARMACEUTICALS GMBH | 2005-11-10 | — | — | US | disclosed |
| US-20050239713-A1 | Novel tubulysin analogues | R&D-BIOPHARMACEUTICALS AM (DE) | 2005-10-27 | — | — | US | disclosed |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2005-09-29 | — | — | US | disclosed |
| EP-1551829-A2 | NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-20050049283-A1 | Compounds that inhibit factor xa activity | MORPHOCHEM AKTIENGESELLSHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2005-03-03 | — | — | US | disclosed |
| WO-2004099134-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | PROSIDION LTD. (GB) | 2004-11-18 | — | — | WO | disclosed |
| US-20040229848-A1 | Glutaminyl based DP IV-inhibitors | PROSIDION LIMITED (GB) | 2004-11-18 | — | — | US | disclosed |
| WO-2004035569-A2 | NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229848-A1 | Glutaminyl based DP IV-inhibitors | DPP4, DPP3, DNPEP | TAAR1 4833/4885TDP1 1900/4885POLB 1053/4885 |
| US-12616670-B2 | N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infections | CPN1, MME, ANPEP | TAAR1 4145/4885TDP1 4106/4885POLB 1980/4885 |
| US-20050249740-A1 | Tubulysin conjugates | TEK, TEKT1, TSG101 | TAAR1 2236/4885TDP1 1640/4885POLB 4503/4885 |
| US-20050239713-A1 | Novel tubulysin analogues | TEK, TEKT1, NGLY1 | TAAR1 2328/4885TDP1 2455/4885POLB 4710/4885 |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | TAAR1 1044/4885TDP1 966/4885POLB 3053/4885 |
| US-12528783-B2 | PqsR inverse agonists | OPRL1, MTNR1A, QRFPR | TAAR1 267/4885TDP1 4830/4885POLB 3647/4885 |
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | TAAR1 1569/4885TDP1 440/4885POLB 2196/4885 |
| US-20050049283-A1 | Compounds that inhibit factor xa activity | F11, TFPI, SERPINC1 | TAAR1 4509/4885TDP1 3005/4885POLB 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.